Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 4, 1995 - Issue 10
Submit an article Journal homepage
7
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Monthly Update Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Recent developments with investigational drugs potentially useful in the treatment of allergic and inflammatory disorders

Nicholas I Carruthers Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey, 07033, USA
&
James J Kaminski Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey, 07033, USA
Pages 1021-1025 | Published online: 03 Mar 2008

References

  • GLASS M: A critical update of new oral therapies: Focus on 5-lipoxygenase inhibitors and leukotriene 134 recep-tor antagonists. Eur. Resp. Rev. (1995) 5(26):120–123.
  • HARRIS RR, CARTER GW, BELL RL, MOORE JL, BROOKS DW: Clinical activity of leukotriene inhibitors. Int. J. Immunopharmacol. (1995) 17(2):147–156.
  • MORLEY J: New drugs for asthma. Exp. Opin. Invest. Drugs (1995) 4(0:547–549.
  • BROOKS DW: Progress with investigational drugs for the treatment of pulmonary and inflammatory dis-eases. Exp. Opin. Invest. Drugs (1994) 3(2):185–190.
  • SMITH WL, DEWITT DL: Differential interactions of pro- staglandin endoperoxide synthases with nonsteroidal anti-Inflammatory drugs. Curr. Opin. Invest. Drugs (1994) 3:1–11.
  • Drugs of the Future (1995) 20(7).2750–752.
  • Scrip (1995) 2017, 2018:29-30.
  • DRAZEN JM, ISRAEL E: Treatment of chronic stable asthma with drugs active on the 5-lipoxygenase path-way. Int. Arch. Allergy Immunol. (1995) 107(1-3):319–320.
  • DRAZEN JM, ISRAEL E, COHN J, DUBE L: The efficacy of Zileuton in the treatment of asthma: Results of com-bined double-blind placebo-controlled trials. J. Allogy Clin. Immunol. (1995) 95(1 pt. 2):388, Abstract 999.
  • BASHA A, RATAJCYK JD, STEWART AO, BELL RE. CARTER GW, BROOKS DW: SAR on acetylinic N-hydroxy ureas: discovery of ABT-761. 209th American Chemical Society Meeting. Chicago, Illinois (1995): MEDI. Abstract 184.
  • ROSENBERG MA, TORRES MJ, VALENCIA A, GARCIA JJ, MIRANDA A, DRAJESK JF, BRANDWEIN S, LANNI C, BLANCA M: The effect of 5-Lipoxygerase (5-LO) inhibitor ABT-761 on inhaled housedust mite early asthmatic response. J. Allergy Clin. Immunol. (1995) 95(1 pt. 2):352, Abstract 845.
  • Drugs of the Future (1995) 20(3):292.
  • LOCKEY RF, LAVINS BJ, SNADER L: Effects of 13 weeks oftreatment with ICI 204,219 (Accolate8) in patients with mild to moderate asthma. J. Allergy Clin. Immunol. (1999 95(1 Pt. 2):350, Abstract 839.
  • NATHAN RA, GALSS M, SNADER L: Effects of 13 weeks of treatment with ICI 204,2319 (Accolatee) or cromolyn sodium (Intal) in patients with mild to moderate asthma. J. Allergy. Clin. hnmunol. (1995) 95(1 Pt. 2):388, Abstract 990.
  • FDC Reports: The Pink Sheet (1995) 57:16.
  • Scrip (1995) 2036:13.
  • MATZKE M, BECKERMANN B, FRUCHTMANN R, FUGMANN B, GARDINER PJ, GOOSSENS J, HATZELMANN A, JUNGE B, KELDENICH J, KOHLSDORFER C, MOHRS ICH, PEDDING-HAUS RM, RADDATZ S: Leukotriene synthesis inhibitors of the quinoline type: parameters for the optimisation of efficacy. Eur.J. Med. Chem. (1995) 30(Suppl.):441S–451S.
  • JONSSON EW, DAHLEN SE: Leukotrienes and other me-diators of the Schultze-Dale reaction in guinea pig lung parenchyma. Adv. Prostaglandin Thromboxane Leuk-otriene Res. (1995) 23:353–355.
  • Scrip (1995) 2028:8.
  • PARKS TP, HOFFMAN AF, HOMON CA, GRAHAM AG, LAZER ES, CHILTON FH, BORGEAT P, RAIBLE D, SCHUL-MAN E, BASS DA: Inhibition of lipid mediator biosyn-thesis in human inflammatory cells lby BIRM 270. Agents Actions (1995) 46(Suppl.):139–146.
  • HOFFMAN AF, MAINOLFI E, HOMON CA, FARINA PR, PARKS TP: The effects of BIRM 270 on human neutrophil degranulation. Fed. Am. Soc. Exp. Biol. J. (1995) 9(3):Al• stract 1316.
  • MORGAN J, STEVENS R, UZEIL FS, LAU H, HIRSCHHOF wL, MARSHALL P, PALMISANO M, PIRAINO A: Multi! dose pharmacokinetics of a monoaryl amidine co pound (CGS-25029C) and its inhibition of dil droxyleukotriene (LTB4) induced CD11-beta. Cl Pharmacol. Ther. (1995) 57(2):153.
  • LABELLE M, BELT FY M, GAREAU Y, GAUTHIER JY, GU D, GORDON R, GROSSMAN SG, JONES TR, LEBLANC MCALTL1FFE M, MCFARLANE C, MASSON P, METTERS OUIMET N, PATRICK DH, PIECHUTA H, ROCIIETTI SAWYER N, XIANG YB, PICKETT CB, FORD HUTCHINE AW, ZAMBONI RJ, YOUNG RN: Discovery of MK-47I potent orally active leukotriene 134 receptor antagoi devoid of peroxisomal induction. Bioorg. Med. Chem. (1995) 5(3):283–288.
  • REISS TF, I3RONSKY E, KEMP J, GUERREIRO D, ZHANL MK-476, a potent and specific leukotriene D4 (EIT receptor antagonist exhibits a dose response in 1 Inhibition of exercise induced bronchoconstriction the end of a daily dosing interval. J. Invest. Med. (19! 43 (Suppl. 2):275A.
  • Scrip (1995) 2011;21.
  • GROSSMAN J, BRONSKY E, BUSSE W, MONTANARO SOUTHERN L, TINKELMAN D, DUBB J, FAIFERMAN I: multicenter, double blind, placebo-controlled stud', evaluate the safety, tolerability and clinical activ" oral, twice daily Pranlukast (SB 205312) in patients mild to moderate asthma. J. Allergy Clin. Immunol. 95(1) Pt. 2:352 Abstr. 846.
  • PharmaProjects (1995):12255.
  • PharmaProjects (1995):12583.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.